Pruritus – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Pruritus – Pipeline Review, H1 2018’, provides an overview of the Pruritus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Pruritus

– The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects

– The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pruritus

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Allergan Plc

Amgen Inc

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Celgene Corp

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

Japan Tobacco Inc

NeuroCycle Therapeutics GmbH

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Sienna Biopharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tesaro Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pruritus Overview

Pruritus Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pruritus Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pruritus Companies Involved in Therapeutics Development

Albireo Pharma Inc

Allergan Plc

Amgen Inc

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Celgene Corp

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

Japan Tobacco Inc

NeuroCycle Therapeutics GmbH

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Sienna Biopharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tesaro Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Vanda Pharmaceuticals Inc

Pruritus Drug Profiles

A-4250 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-8379 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asimadoline Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-008 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-244 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bepotastine besilate SR Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

difelikefalin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTS-661 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalbuphine hydrochloride ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalfurafine hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemolizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPK-88002 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant maleate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATN-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch Drug Profile

Product Description

Mechanism Of Action

R&D Progress

phenylbutyrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-38 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-1609 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1405 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Pruritus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize KOR1 for Pruritus Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-120 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPU-010 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VVZ-149 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pruritus Dormant Projects

Pruritus Discontinued Products

Pruritus Product Development Milestones

Featured News & Press Releases

Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125

Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis

Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting

Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120

Oct 17, 2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017

Oct 17, 2017: Menlo Therapeutics Expands its Management Team

Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017

Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017

Sep 22, 2017: Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH CAPSULES

2.5µg and REMITCH OD Tablets

2.5µg

Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology

Sep 13, 2017: Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis

Aug 01, 2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer

Jun 23, 2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pruritus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pruritus Pipeline by Albireo Pharma Inc, H1 2018

Pruritus Pipeline by Allergan Plc, H1 2018

Pruritus Pipeline by Amgen Inc, H1 2018

Pruritus Pipeline by Amorepacific Corp, H1 2018

Pruritus Pipeline by Asana BioSciences LLC, H1 2018

Pruritus Pipeline by Cara Therapeutics Inc, H1 2018

Pruritus Pipeline by Celgene Corp, H1 2018

Pruritus Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Pruritus Pipeline by ELORAC Inc, H1 2018

Pruritus Pipeline by GlaxoSmithKline Plc, H1 2018

Pruritus Pipeline by Hydra Biosciences Inc, H1 2018

Pruritus Pipeline by Japan Tobacco Inc, H1 2018

Pruritus Pipeline by NeuroCycle Therapeutics GmbH, H1 2018

Pruritus Pipeline by Patagonia Pharmaceuticals LLC, H1 2018

Pruritus Pipeline by Patara Pharma Inc, H1 2018

Pruritus Pipeline by RDD Pharma Ltd, H1 2018

Pruritus Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018

Pruritus Pipeline by Sienna Biopharmaceuticals Inc, H1 2018

Pruritus Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Pruritus Pipeline by Teikoku Pharma USA Inc, H1 2018

Pruritus Pipeline by Tesaro Inc, H1 2018

Pruritus Pipeline by Tioga Pharmaceuticals Inc, H1 2018

Pruritus Pipeline by Toray Industries Inc, H1 2018

Pruritus Pipeline by Vanda Pharmaceuticals Inc, H1 2018

Pruritus Dormant Projects, H1 2018

Pruritus Dormant Projects, H1 2018 (Contd..1), H1 2018

Pruritus Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Pruritus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports